Intracerebral Hemorrhage Clinical Trial
— FMIICHOfficial title:
Efficacy and Safety of Fingolimod in Minimal Invasive Treatment of Intracerebral Hemorrhage
Verified date | October 2023 |
Source | Tang-Du Hospital |
Contact | Zhihong Li |
Phone | +86-13709183909 |
409615390[@]qq.com | |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Intracerebral hemorrhage (ICH) is a critical disease of public health importance. Inflammatory mechanisms play a significant role in ICH. Thus, immune targets are supposed to be effective in protecting the neurological function of ICH. Fingolimod, a sphingosine-1-phosphate receptor regulator (FTY720), is an effective immunology modulator. It has been widely used in autoimmune disease and has also been testified effective in ICH who received conservative treatment. The present study aims to evaluate the efficiency and safety of fingolimod for ICH with minimal invasive treatment.
Status | Not yet recruiting |
Enrollment | 40 |
Est. completion date | December 30, 2025 |
Est. primary completion date | June 30, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: - spontaneous basal ganglia ICH with volume larger than 20ml; - age: 18-80 years; - admission Glasgow Coma Scale score: 5-12; - admitting to hospital with 24 hours after injury; - no fever or signs infection on admission to hospital; - admission heart rate=60/min on admission. Exclusion Criteria: - refuse follow-up; - received operation before admitting to hospital; - hemorrhage by tumor, arteriovenous malformation, arterial aneurysm, hematological disease or traumatic brain injury; - severe vomiting; - mRS>1 before ICH; - prior history of bradycardia; - prior history of Atrioventricular block; - prior history of traumatic brain injury, craniotomy or stroke; - expected lifetime less than 1 year; - undergoing antitumor, antiepileptic, immunomodulatory or immunosuppressive therapy; - admitting to other ongoing study; - systemic disease: uremia, liver cirrhosis, malignant tumor, mental disease, drug or alcohol dependence; - received anticoagulant or antiplatelet therapy within 7 days; - intraventricular hemorrhage requires intraventricular catheterization. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Tang-Du Hospital |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | modified Rankin Scale | Neurological outcome, range: 0-6. The higher scores mean a worse outcome. | 90 days and 180 days after ICH | |
Secondary | The National Institutes of Health Stroke Scale | Neurological outcome, range: 0-42. The higher scores mean a worse outcome. | 90 days and 180 days after ICH | |
Secondary | Modified Barthel Index | Neurological outcome, range: 0-100. The higher scores mean a better outcome. | 90 days and 180 days after ICH | |
Secondary | Montreal Cognitive Assessment Scale | Neurological outcome, range: 0-30. The higher scores mean a better outcome. | 90 days and 180 days after ICH | |
Secondary | Volume of perihematomal edema | Volume of perihematomal edema measured on head Computerised Tomography | Baseline on admission, 7 days and 14 days after ICH |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05089331 -
ROSE-Longitudinal Assessment With Neuroimaging
|
||
Recruiting |
NCT03605381 -
MORbidity PRevalence Estimate In StrokE
|
||
Active, not recruiting |
NCT04522102 -
Antiplatelet Secondary Prevention International Randomised Trial After INtracerebral haemorrhaGe (ASPIRING)-Pilot Phase
|
Phase 3 | |
Terminated |
NCT04178746 -
PRONTO: Artemis in the Removal of Intraventricular Hemorrhage in the Hyper-Acute Phase
|
||
Not yet recruiting |
NCT03956485 -
Multicentre Registry of Patients With Spontaneous Acute Intracerebral Hemorrhage in Catalonia (HIC-CAT).
|
||
Enrolling by invitation |
NCT02920645 -
Multicenter Validation of the AVICH Score
|
N/A | |
Recruiting |
NCT02625948 -
Tranexamic Acid for Acute ICH Growth prEdicted by Spot Sign
|
Phase 2 | |
Completed |
NCT02478177 -
Addressing Real-world Anticoagulant Management Issues in Stroke
|
||
Completed |
NCT01971359 -
Clinical Outcomes Following Parafascicular Surgical Evacuation of Intracerebral Hemorrhage: A Pilot Study
|
N/A | |
Completed |
NCT01261091 -
Early Tracheostomy in Ventilated Stroke Patients
|
N/A | |
Terminated |
NCT00990509 -
Albumin for Intracerebral Hemorrhage Intervention
|
Phase 2 | |
Completed |
NCT00716079 -
The Second Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial
|
N/A | |
Recruiting |
NCT00222625 -
rFVIIa in ICH in Patients Treated With Anticoagulants or Anti-Platelets
|
Phase 2 | |
Recruiting |
NCT05095857 -
The Anesthetic Ketamine as Treatment for Patients With Severe Acute Brain Injury
|
Phase 4 | |
Recruiting |
NCT04548596 -
NOninVasive Intracranial prEssure From Transcranial doppLer Ultrasound Development of a Comprehensive Database of Multimodality Monitoring Signals for Brain-Injured Patients
|
||
Not yet recruiting |
NCT06429332 -
International Care Bundle Evaluation in Cerebral Hemorrhage Research
|
Phase 4 | |
Recruiting |
NCT05492474 -
Cranial Ultrasound for Prehospital ICH Diagnosis
|
N/A | |
Not yet recruiting |
NCT05502874 -
Multicenter Registry for Assessment of Markers of Early Neurological Deterioration in Primary Intracerebral Hemorrhage
|
||
Recruiting |
NCT04604587 -
MRI-visible Enlarged Perivascular Spaces and the Alteration of Lymphatic Drainage System in CAA
|
Phase 3 | |
Recruiting |
NCT05504941 -
Detection of an Endovascular Treatment Target in Patients With an Acute, Spontaneous Intracerebral Hemorrhage
|
N/A |